All News

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Your daily dose of the clinical news you may have missed.

Individuals newly classified with obesity using the European framework were found to be overall sicker and at greater risk for mortality.

Obesity medicine expert Bonnet answers questions about the downsides of GLP-1 therapy for obesity management and how lifestyle medicine interventions will help.

Richard Rosenfeld, MD, MPH, MBA, led the development of lifestyle medicine guidelines to treat or even reverse prediabetes and type 2 diabetes.

The Danish study analyzed a nationwide cohort of 2.1 million children and found no association between aluminum exposure and allergic, autoimmune, or neurodevelopmental conditions.

Your daily dose of the clinical news you may have missed.

A new analysis of the CAHtalog phase 3 study showed approximately 95% of participants experienced either high glucocorticoid exposure or elevated androstenedione levels during treatment.

Monu Khanna, MD, discusses the benefits of behavioral strategies, including yoga, breathwork, and dancing, in reducing cardiovascular disease risk in patients with obesity.

Maternal depression significantly disrupts parenting behaviors, impacting child development and emotional bonding, according to an updated international literature review.

Lead author for the American College of Lifestyle Medicine's new clinical practice guideline discusses the broad endorsement for the recommendations across participating groups.

ENDO 2025. Older adults, rural populations, and residents in the Midwest experienced the highest mortality rates, according to new data.

GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.

Treatment should address root causes, including lifestyle modifications, stress management, and gut health, Monu Khanna, MD, told Patient Care.

The abrupt cancellation, without warning or cause, has medical groups and health care leaders concerned about patient access to no-cost preventive services.